J
James Galloway
Researcher at King's College London
Publications - 265
Citations - 5953
James Galloway is an academic researcher from King's College London. The author has contributed to research in topics: Rheumatoid arthritis & Medicine. The author has an hindex of 29, co-authored 233 publications receiving 4105 citations. Previous affiliations of James Galloway include North Manchester General Hospital & Weston Education Centre.
Papers
More filters
Journal ArticleDOI
Drug-specific risk of tuberculosis in patients with rheumatoid arthritis treated with anti-TNF therapy: results from the British Society for Rheumatology Biologics Register (BSRBR)
William G Dixon,Kimme L. Hyrich,Kath D. Watson,Mark Lunt,James Galloway,Andrew Ustianowski,Deborah P M Symmons +6 more
TL;DR: The rate of TB in patients with RA treated with anti-TNF therapy was three- to fourfold higher in patients receiving INF and ADA than in those receiving ETA.
Journal ArticleDOI
Anti-TNF therapy is associated with an increased risk of serious infections in patients with rheumatoid arthritis especially in the first 6 months of treatment: updated results from the British Society for Rheumatology Biologics Register with special emphasis on risks in the elderly
James Galloway,Kimme L. Hyrich,Louise K. Mercer,William G Dixon,Bo Fu,Andrew Ustianowski,Kath D. Watson,Mark Lunt,Deborah P M Symmons +8 more
TL;DR: In this article, the authors evaluated the risk of serious infections (SIs) in patients with RA treated with anti-TNF therapy with emphasis on the risk across different ages using data from the British Society for Rheumatology Biologics Register, a prospective observational study.
Journal ArticleDOI
A systematic review and meta-analysis of infection risk with small molecule JAK inhibitors in rheumatoid arthritis
Katie Bechman,Sujith Subesinghe,Sam Norton,Fabiola Atzeni,Massimo Galli,Andrew P. Cope,Kevin L. Winthrop,James Galloway +7 more
TL;DR: The absolute SI rates were low, however across the JAK inhibitors, the incidence of HZ is higher than expected for the population (3.23 per 100 patient-years).
Journal ArticleDOI
Risk of septic arthritis in patients with rheumatoid arthritis and the effect of anti-TNF therapy: results from the British Society for Rheumatology Biologics Register
James Galloway,Kimme L. Hyrich,Louise K. Mercer,William G Dixon,Andrew Ustianowski,Matthew Helbert,Kath D. Watson,Mark Lunt,Deborah P M Symmons +8 more
TL;DR: Anti-TNF therapy use in RA is associated with a doubling in the risk of septic arthritis, and Physicians and surgeons assessing the RA patient should be aware of this potentially life-threatening complication.